Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long term lithium treatment initiated during development (5–6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9–11 months of age restores normal mGluR-LTD. Additionally, chronic short term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inositol trisphosphate and calcium signalling
Berridge, M. J. (1993) · Nature · doi:10.1038/361315a0 · Cited by 6,545 · cited 2×
“Lithium can also inhibit this downstream pathway as it can InsP3R-mediated calcium signaling through inhibition of IMPase and IPPase (Acharya et al., 1998; Baraban et al., 1989; Berridge, 1993; Berridge et al., 1989; Hallcher and Sherman, 1980).”
BackgroundMalenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968 · cited 1×
“This is both very interesting and important as it is widely accepted that long-term depression (LTD) as well as long-term potentiation (LTP) are cellular models of learning and memory (Altinbilek and Manahan-Vaughan, 2009; Kelleher et al., 2004; Malenka and Bear, 2004; Whitlock et al., 2006).”
Self-citationLearning induces long-term potentiation in the hippocampus
Whitlock, J. R., Heynen, A. J., Shuler, M. G., & Bear, M. F. (2006) · Science · doi:10.1126/science.1128134 · Cited by 1,913
Self-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“This is both very interesting and important as it is widely accepted that long-term depression (LTD) as well as long-term potentiation (LTP) are cellular models of learning and memory (Altinbilek and Manahan-Vaughan, 2009; Kelleher et al., 2004; Malenka and Bear, 2004; Whitlock et al., 2006).”
BackgroundSelf-citationAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Self-citationFragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051 · cited 2×
“…it is known to be enriched both presynaptically and postsynaptically, and is associated with and regulates a number of mRNAs in response to synaptic activity (Bassell and Warren, 2008; Jacquemont et al., 2007; Kelleher and Bear, 2008; Ronesi and Huber, 2008; Wang et al., 2010; Zukin et al., 2009).”
BackgroundCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Self-citationA family of metabotropic glutamate receptors
Tanabe, Y., Masu, M., Ishii, T., Shigemoto, R., & Nakanishi, S. (1992) · Neuron · doi:10.1016/0896-6273(92)90118-w · Cited by 940
The Autistic Neuron: Troubled Translation?
Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598 · cited 1×
“…it is known to be enriched both presynaptically and postsynaptically, and is associated with and regulates a number of mRNAs in response to synaptic activity (Bassell and Warren, 2008; Jacquemont et al., 2007; Kelleher and Bear, 2008; Ronesi and Huber, 2008; Wang et al., 2010; Zukin et al., 2009).”
BackgroundSelf-citationTranslational Regulatory Mechanisms in Persistent Forms of Synaptic Plasticity
Kelleher, R. J., Govindarajan, A., & Tonegawa, S. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.013 · Cited by 592
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370
“…both pharmacological and genetic approaches in evolutionarily distant animal models (Aschrafi et al. 2005; Bolduc et al. 2008; Chang et al. 2008; Choi et al. 2010, 2011; Chuang et al. 2005; de Vrij et al. 2008; Dolen et al. 2007; Hays et al. 2011; Koekkoek et al. 2005; Levenga et al. 2011; Liu…”
BackgroundSelf-citationOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230
Self-citationUnifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops
Mullins, C., Fishell, G., & Tsien, R. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.017 · Cited by 167
Autism and the synapse: emerging mechanisms and mechanism-based therapies
Ebrahimi-Fakhari, D., & Sahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 167
GSK-3 β at the Intersection of Neuronal Plasticity and Neurodegeneration
Jaworski, T., Banach-Kasper, E., & Gralec, K. (2019) · Neural Plasticity · doi:10.1155/2019/4209475 · Cited by 159
“Interestingly, further research showed aberrant mGluR signaling to GSK-3 in FX mice, and lithium treatment normalized increased mGluR-dependent LTD at CA1 synapses in these mice [122].”
BackgroundTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
First glimpses of the neurobiology of autism spectrum disorder
Sanders, S. J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.10.002 · Cited by 84
Kiser, D. P., Rivero, O., & Lesch, K. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12392 · Cited by 58
“…and plasticity (Choi et al., 2011; Tranfaglia, 2011), and proper functioning of glutamatergic and GABAergic signaling pathways (Bear, Huber, & Warren, 2004; Busquets-Garcia et al., 2013; Choi et al., 2011; D’Hulst & Kooy, 2007; D’Hulst et al., 2006, 2009; D€olen & Bear, 2008; D€olen et al., 2007).”
BackgroundDe Rubeis, S., Fernández, E., Buzzi, A., Di Marino, D., & Bagni, C. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_23 · Cited by 48
Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, J., Rosenfelt, C., Gertner, M. J., Campbell, S. R., Emerson, D., Hinchey, P., Kollaros, M., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00136 · Cited by 46
“Chronic treatments of fragile X mice with lithium, group I mGluR antagonists, group II mGluR antagonists and PDE-4 inhibitors have been demonstrated to abrogate the enhanced mGluR-LTD phenotype (Choi et al., 2011, 2015; Michalon et al., 2012).”
BackgroundMethodResultInfluentialSelf-citationHeads‐up: New roles for the fragile X mental retardation protein in neural stem and progenitor cells
Callan, M. A., & Zarnescu, D. C. (2011) · genesis · doi:10.1002/dvg.20745 · Cited by 39
“Although promising therapies are currently being developed based on rescuing well documented defects in glutamate receptor signaling (Bear, 2005; Choi et al., 2011; Dölen and Bear, 2005; Dölen et al., 2007; McBride et al., 2005; Yan et al., 2005), the high frequency of FXS as well as the…”
Background
Metadata
- Authors
- Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, P., Kollaros, M., Gertner, M. J., Woo, N. H., Tranfaglia, M. R., Bear, M. F., Zukin, R. S., McDonald, T. V., Jongens, T. A., & McBride, S. M. J.
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 1380
- Pages
- 106-119
- ISSN
- 0006-8993 (ISSN-L)
- OpenAlex
- W1968117010
- Cited by
- 104
- References
- 21
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.